Literature DB >> 18803444

Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits.

Junjie Zhang1, Liya Wang, Changfeng Gao, Li Zhang, Huiyun Xia.   

Abstract

PURPOSE: The aim of this study was to develop an aqueous ketoconazole (KET) eye drop in order to increase the corneal permeability and improve ocular bioavailability following topical application.
METHODS: Hydroxypropyl beta-cyclodextrin (HP-beta-CD) was used to formulate an aqueous eye drop to improve the aqueous solubility of KET. A single dose of of either KET suspension (1.5%; KET-SP) or KET (1.5%)/HP-beta -CD (12.5%) solution (KET-CD) was applied to rabbits. Aqueous humor and cornea were collected after 5, 10, 20, 30, 45, 60, 90, 120, and 180 min. KET concentrations were determined by high-performance liquid chromatography after extraction.
RESULTS: After topically applying KET-CD, the KET concentrations in aqueous humor were significantly increased at 10 approximately 120 min, compared with those of KET-SP (P < 0.05), whereas KET concentrations became undectable at 180 min after topically applying KET-SP. The highest levels of KET in aqueous humor (Cmax, 2.67 microg/mL) were obtained after a 20-min application of KET-CD, 6.1 times greater than that corresponding to the KET-SP at 30 min. The KET concentrations in aqueous humor for post-120- and 180-min instillations of KET-CD were 57.9 and 34.5 times higher than that of KET-SP post-120 min, respectively. The KET-CD produced an over eightfold bioavailability (AUC(0-120), area under the concentration-time curve between 0 and 120 min) increase in aqueous humor over the KET-SP. Peak KET concentration in the cornea (118.24 microg/g) was achieved within 5 min after the instillation of KET-CD, 18.4 times higher than that of KET-SP at the same time point, whereas the highest KET level in cornea was only 8.57 microg/g after a 10-min application of KET-SP. The KET levels in corneas obtained after the application of KET-CD were all much higher than those obtained by KETSP (P < 0.01). The KET-CD produced an over twelvefold bioavailability (AUC(0-120)) increase in corneas over the KET-SP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803444     DOI: 10.1089/jop.2008.0015

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  5 in total

1.  Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies.

Authors:  Ghada A Abdelbary; Maha M Amin; Mohamed Y Zakaria
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring.

Authors:  Abeer H A Mohamed-Ahmed; Alastair Lockwood; He Li; Maryse Bailly; Peng T Khaw; Steve Brocchini
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-07-01       Impact factor: 4.799

3.  A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole.

Authors:  Tarek Abdelnapy Ahmed; Bader M Aljaeid
Journal:  Int J Nanomedicine       Date:  2017-03-08

Review 4.  Update on diagnosis and management of refractory corneal infections.

Authors:  Shweta Agarwal; Tanveer A Khan; Murugesan Vanathi; Bhaskar Srinivasan; Geetha Iyer; Radhika Tandon
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

5.  Lidocaine Cyclodextrin complex Ophthalmic Drop, a New Topical Anesthetic Choice.

Authors:  Aa Sabermoghadam Ranjbar; O Rajabi; R Salari; H Ashraf
Journal:  Iran Red Crescent Med J       Date:  2012-09-30       Impact factor: 0.611

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.